Curium US LLC Archives | Be Korea-savvy

Home / Posts tagged Curium US LLC

Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China

Curium’s Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre for Drug Evaluation (CDE) and it is now under review BOSTON, Jan. 07, 2026 (Korea Bizwire) – Curium Shanghai Pharmaceuticals Co., Ltd. (科锐霖（上海）医药有限公司), has had its Investigational New Drug (IND) application [...]

Curium Establishes Legal Entity in China

Curium has established a legal entity in China which represents a major milestone in Curium’s international growth strategy and will enhance Curium’s ability to serve patients with cancer across Asia Curium’s local footprint will strengthen collaboration with key partners and align with their long-term vision to build a next-generation pipeline of radiopharmaceuticals for therapy BOSTON, [...]

CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally

Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle The transaction values Curium at circa $7 billion, representing the largest transaction in nuclear medicine globally The recapitalization will accelerate Curium’s strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients around the world BOSTON, Nov. 20, 2025 (Korea [...]

Curium Consolidates New Biopharma Business and Sets Up Global Headquarters in Boston, Massachusetts

Curium Biopharma will continue to lead discovery and new product development Strategic move aims to accelerate biopharma innovation and revolutionize the diagnosis and treatment of cancer Curium International headquarters remain in Paris, France, while the United States headquarters are in St Louis, Missouri ST. LOUIS, Nov. 17, 2025 (Korea Bizwire) – Curium, a company dedicated [...]

Curium Group, PeptiDream and PDRadiopharma Enroll First Patient to Registrational Clinical Trial of 64Cu-PSMA-I&T for Prostate Cancer in Japan

A Registrational Phase 2 clinical trial has been initiated for 64Cu-PSMA-I&T – a PET radiopharmaceutical targeting prostate-specific membrane antigen (PSMA) expressed on prostate cancer cells PARIS, Oct. 15, 2025 (Korea Bizwire) – Curium Group announced today that together with PeptiDream Inc. and PDRadiopharma Inc., a registrational Phase 2 clinical trial has been initiated in Japan for 64Cu-PSMA-I&T [...]

Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals

Global supply of technetium-99m, most widely used medical isotopes in nuclear medicine, is secured for the coming years PETTEN, The Netherlands, May 21, 2025 (Korea Bizwire) — NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which transforms into technetium-99, is a critical isotope used in nuclear [...]

Curium strengthens its PET manufacturing capacity and expands European footprint with the acquisition of Nucleis

The acquisition of Nucleis will: Enhance Curium’s PET manufacturing capacity and radiopharmaceutical distribution network of 32 PET sites in Western Europe Improve reliability and accessibility of life-saving PET diagnostics for patients in Benelux and Germany Expand CDMO capabilities to support the development of innovative PET tracers in oncology, neurology, and cardiology PARIS, April 10, 2025 [...]

Curium Announces Strategic Partnership with PeptiDream for Prostate Cancer Theranostics in Japan

Collaboration to include the clinical development, regulatory filing, and commercialization in Japan of 177Lu-PSMA-I&T and 64Cu-PSMA-I&T Builds on long-standing relationship between the two companies In Japan around 90,000 new cases of prostate cancer are diagnosed each year PARIS, Oct. 01, 2024 (Korea Bizwire) – Curium, a world leader in nuclear medicine, announced today that it has entered [...]